高敏肌钙蛋白T预测NSCLC放化疗心脏毒性的预后价值
该研究为前瞻性随机试验的二次分析,纳入225例接受同步铂类联合紫杉类双药化疗及胸部放疗(总剂量60-74 Gy)的非小细胞肺癌患者,其中190例有连续hs-cTnT检测。结果显示≥3级心脏不良事件发生于24例(11%),中位间隔9个月;放化疗前hs-cTnT>10 ng/L或治疗期间Δ≥5 ng/L与严重心脏不良事件及死亡风险显著增加相关。
要点
- 放化疗期间hs-cTnT升高呈心脏剂量依赖性,与平均心脏剂量及心脏V5-V55相关。
- 基线hs-cTnT>10 ng/L或治疗期间Δ≥5 ng/L提示严重心脏不良事件及死亡风险增加。
- 常规监测hs-cTnT或可早期识别放化疗心脏毒性高危患者。
核心结论
- 放化疗期间hs-cTnT升高与心脏受照剂量相关,且高hs-cTnT水平与心脏不良事件及死亡相关。
研究设计与样本
- 前瞻性随机试验的二次分析,纳入225例接受同步铂类联合紫杉类双药化疗及胸部放疗(总剂量60-74 Gy)的非小细胞肺癌患者,其中190例有连续hs-cTnT检测。
主要发现
- 24例(11%)发生≥3级心脏不良事件,中位间隔为放化疗后9个月。
- 放化疗前hs-cTnT在男性、年龄≥64岁、已有心脏病或体能状态差的患者中更高(P<.05)。
- hs-cTnT在放化疗第4周升高(P<.05),放化疗结束后下降但未恢复至治疗前水平(P=.002)。
- 放化疗期间hs-cTnT变化(Δ)与平均心脏剂量(P=.0004)、心脏V5-V55(P<.05)及肿瘤位置(P=.006)相关。
- 放化疗前hs-cTnT>10 ng/L或治疗期间Δ≥5 ng/L时,严重心脏不良事件及死亡风险显著增加。
关键数值与推荐
- 放化疗前hs-cTnT>10 ng/L或放化疗期间Δ≥5 ng/L与严重心脏不良事件及死亡风险显著增加相关。
临床怎么用
- 常规监测hs-cTnT或可早期识别放化疗诱导心脏不良事件高危患者,以指导治疗调整和干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cardiotoxicities induced by cancer therapy can negatively affect quality of life and survival. We investigated whether high-sensitivity cardiac troponin T (hs-cTnT) levels could serve as biomarker for early detection of cardiac adverse events (CAEs) after chemoradiation therapy (CRT) for non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This study included 225 patients who received concurrent platinum and taxane-doublet chemotherapy with thoracic radiation therapy to a total dose of 60 to 74 Gy for NSCLC. All patients were evaluated for CAEs; 190 patients also had serial hs-cTnT measurements. RESULTS: Grade ≥3 CAEs occurred in 24 patients (11%) at a median interval of 9 months after CRT. Pretreatment hs-cTnT levels were higher in men, in patients aged ≥64 years, and in patients with pre-existing heart disease or poor performance status (P < .05). hs-cTnT levels increased at 4 weeks during CRT (P < .05) and decreased after completion of CRT but did not return to pretreatment levels (P = .002). The change (Δ) in hs-cTnT levels during CRT correlated with mean heart dose (P = .0004), the heart volumes receiving 5 to 55 Gy (P < .05), and tumor location (P = .006). Risks of severe CAEs and mortality were significantly increased if the pretreatment hs-cTnT was >10 ng/L or the Δ during CRT was ≥5 ng/L. CONCLUSIONS: Elevation of hs-cTnT during CRT was radiation heart dose-dependent, and high hs-cTnT levels during the course of CRT were associated with CAEs and mortality. Routine monitoring of hs-cTnT could identify patients who are at high risk of CRT-induced CAEs early to guide modifications of cancer therapy and possible interventions to mitigate cardiotoxicity.
引用
- Xu T, Meng QH, Gilchrist SC, et al. Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 34302893. doi:10.1016/j.ijrobp.2021.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。